This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
DJ Dooley , CA Mieske , SA Borosky (2000 b). Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neuroscience Letters 280, 107–110.
JC Fehrenbacher , CP Taylor , MR Vasko (2003). Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105, 133–144.
JP Feighner , JB Cohn (1989). Analysis of individual symptoms in generalized anxiety – a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 21, 124–130.
DE Feltner , JG Crockatt , SJ Dubovsky , CK Cohn , (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240–249.
X Fink , DJ Dooley , WP Meder , N Suman-Chauhan , (2002). Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229–236.
NS Gee , JP Brown , VU Dissanayake , J Offord , (1996). The novel anticonvulsant drug, gabapentin (neurontin), binds to the alpha2delta subunit of a calcium channel. Journal of Biological Chemistry 271, 5768–5776.
M Hamilton (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 5055.
M Hamilton (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278–296.
S Kasper , B Herman , G Nivoli , M van Ameringen , (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International Clinical Psychopharmacology 24, 87–96.
IR Katz , CF Reynolds , GS Alexopoulos , D Hackett (2002). Venlafaxine ER as a treatment for generalized anxiety disorders in older adults: pooled analysis of five randomized placebo-controlled trials. Journal of the American Geriatric Society 50, 18–25.
RC Kessler , WT Chiu , O Demler , KR Merikangas , EE Walters (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 617–627.
YP Maneuf , J Hughes , AT McKnight (2001). Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain 93, 191–196.
P Meoni , D Hackett , M Lader (2004). Pooled analysis of venlafaxine XR efficacy on psychic and somatic symptoms of anxiety in patients with generalized anxiety disorder. Depression and Anxiety 19, 127–132.
P Meoni , E Salinas , Y Brault , D Hackett (2001). Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Journal of Clinical Psychiatry 62, 888–893.
SA Montgomery , K Tobias , GL Zornberg , S Kasper , AC Pande (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry 67, 771–782.
RB Pohl , DE Feltner , RR Fieve , AC Pande (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 25, 151–158.
MH Pollack , R Zaninelli , A Goddard , JP McCafferty , (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350–357.
A Raskin , J Schulterbrandt , N Reatig , JJ McKeon (1969). Replication of factors of psychopathology in interview, ward behaviour and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Diseases 148, 87–98.
JL Rhudy , MW Meagher (2000). Fear and anxiety: divergent effects on human pain thresholds. Pain 84, 65–75.
K Rickels , R Downing , E Schweizer , H Hassman (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 50, 884–895.
K Rickels , MH Pollack , DE Feltner , RB Lydiard , (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62, 1022–1030.
K Rickels , MH Pollack , DV Sheehan , JT Haskins (2000). Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 157, 968–974.
K Rickels , E Schweizer , I Csanalosi , WG Case , H Chung (1988). Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Archives of General Psychiatry 45, 444–450.
K Rickels , R Zaninelli , J McCafferty , K Bellew , (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749–756.
DS Robinson , A Khan (2004). Dosing strategies for antidepressant clinical trials: a commentary. Journal of Clinical Psychopharmacology 24, 1–3.
CP Taylor , MG Vartanian , PW Yuen , C Bigge , (1993). Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Research 14, 11–15.
KA Yonkers , SE Bruce , IR Dyck , MB Keller (2003). Chronicity, relapse, and illness – course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depression and Anxiety 17, 173–179.